{
  "source": "PA-Med-Nec-Oriahnn-Myfembree.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2216-7\nProgram Prior Authorization/Medical Necessity\nMedication Oriahnn® (elagolix and estradiol/norethindrone), MyFembree® (relugolix\nand estradiol hemihydrate/norethindrone)\nP&T Approval Date 9/2020, 8/2021, 1/2022, 9/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nOriahnn, elagolix, co-packaged with estradiol/norethindrone, and MyFembree, relugolix co-\npackaged with estradiol hemihyrate/norethindrone, are gonadotropin-releasing hormone (GnRH)\nreceptor antagonists co-packaged with a combined oral contraceptive, is indicated for the\nmanagement of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in\npremenopausal women. Myfembree is also indicated for the management of moderate to severe\npain associated with endometriosis in premenopausal women.\n2. Coverage Criteriaa:\nA. Uterine Fibroids\n1. Initial Authorization\na. MyFembree and Oriahnn will be approved based on all of the following criteria:\n1) Diagnosis of uterine fibroids (leiomyomas)\n-AND-\n2) Used for the management of heavy menstrual bleeding\n-AND-\n3) Failure after a three-month trialb, contraindication, or intolerance to one of the\nfollowing:\na) Estrogen/progestin contraceptive (e.g. Loestrin FE®)\nb) Progestin-releasing intrauterine devices (IUDs) (e.g. Mirena®)\nc) Progestin-only contraceptive [e.g., norethindrone (generic Micronor®)]\n-AND-\n4) Prescribed by or in consultation with one of the following:\na) Obstetrics/Gynecologist (OB/GYN)\nb) Reproductive endocrinologist\n© 2025 UnitedHealthcare Services Inc.\n1\nAuthorization will be issued for 12 months\n2. Reauthorization\na. MyFembree and Oriahnn will be approved based on all of the following criteria:\n1) Documentation of positive clinical response to therapy\n2) Impact to bone mineral density has been considered\n3) Treatment duration has not exceeded a total of 24 months\nAuthorization will be issued for 12 months up to a maximum treatment duration o",
    "herapy\n2) Impact to bone mineral density has been considered\n3) Treatment duration has not exceeded a total of 24 months\nAuthorization will be issued for 12 months up to a maximum treatment duration of 24\nmonths\nNOTE: MyFembree and Oriahnn are indicated for a maximum treatment duration of\n24 months\nB. Pain associated with Endometriosis\n1. Initial Authorization\na. MyFembree will be approved based on all of the following criteria:\n1) Diagnosis of moderate to severe pain associated with endometriosis\n-AND-\n2) Failureb after a three-month trialb (e.g., inadequate pain relief), contraindication or\nintolerance of two analgesics (e.g., ibuprofen, meloxicam, naproxen)\n-AND-\n3) Failure after a three-month trialb, contraindication, or intolerance to one of the\nfollowing:\na) Hormonal contraceptives\nb) Progestins [e.g., norethindrone (generic Aygestin)]\n-AND-\n4) Prescribed by or in consultation with one of the following:\na) Obstetrics/Gynecologist (OB/GYN)\nb) Reproductive endocrinologist\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Myfembree will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services Inc.\n2\n(1) Documentation of positive clinical response to therapy\n(2) Impact to bone mineral density has been considered\n(3) Treatment duration has not exceeded a total of 24 months\nAuthorization will be issued for 12 months up to a maximum treatment duration of 24\nmonths\nNOTE: MyFembree is indicated for a maximum treatment duration of 24 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\nb For Connecticut, Kentucky and Mississippi business, only a 30 day trial will be required..\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD",
    "d..\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Oriahnn [package insert]. North Chicago, IL: AbbVie Inc.; June 2023.\n2. MyFembree [package insert]. Marlsborough, MA: Sumito Pharma America, Inc; July 2024.\n3. The American College of Obstetricians and Gynecologists. Management of Symptomatic Uterine\nLeiomyomas. Practice Bulletin 228. June 2021.\n4. The American College of Obstetricians and Gynecologists. Management of endometriosis.\nPractice Bulletin 114. July 2010 (Reaffirmed 2018).\nProgram Prior Authorization/Medical Necessity – Oriahnn, MyFembree\nChange Control\nDate Change\n9/2020 New program\n8/2021 Annual review. Added MyFembree.\n1/2022 Removed the tranexamic acid requirement. Updated the state mandate\nlanguage. Updated references.\n9/2022 Added new indication for pain associated with endometriosis for\nMyfembree. Updated state mandate language to include Mississippi.\n2/2023 Removed the criteria that patient is premenopausal. Updated references.\n2/2024 Annual review. Updated failure language. Updated state mandate\nlanguage. Updated authorization duration. Updated references.\n2/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}